Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 46 entries
Sorted by: Best Match Show Resources per page
[New therapeutic options in multiple sclerosis].

Fortschritte der Neurologie-Psychiatrie

Salmen A, Chan A.
PMID: 25794324
Fortschr Neurol Psychiatr. 2015 Mar;83(3):174-86. doi: 10.1055/s-0034-1399247. Epub 2015 Mar 20.

Therapeutic options in the treatment of multiple sclerosis (MS) have broadened notably over the past years, especially for relapsing-remitting forms of MS. The revision of the diagnostic criteria simplified and accelerated MS diagnosis, definitions of disease courses were operationalized...

Cite
Salmen A, Chan A. Neue Therapieoptionen bei der Multiplen Sklerose. [New therapeutic options in multiple sclerosis]. Fortschr Neurol Psychiatr. 2015;83(3):174-86doi: 10.1055/s-0034-1399247.
Salmen, A., & Chan, A. (2015). Neue Therapieoptionen bei der Multiplen Sklerose. [New therapeutic options in multiple sclerosis]. Fortschritte der Neurologie-Psychiatrie, 83(3), 174-86. https://doi.org/10.1055/s-0034-1399247
Salmen, A, and Chan, A. "Neue Therapieoptionen bei der Multiplen Sklerose." [New therapeutic options in multiple sclerosis]. Fortschritte der Neurologie-Psychiatrie vol. 83,3 (2015): 174-86. doi: https://doi.org/10.1055/s-0034-1399247
Salmen A, Chan A. Neue Therapieoptionen bei der Multiplen Sklerose. [New therapeutic options in multiple sclerosis]. Fortschr Neurol Psychiatr. 2015 Mar;83(3):174-86. doi: 10.1055/s-0034-1399247. Epub 2015 Mar 20. German. PMID: 25794324.
Copy Download .nbib Format: NLM
[Treatment].

Rinsho shinkeigaku = Clinical neurology

Saida T, Tanaka M, Komori M, Hao Q.
PMID: 17432204
Rinsho Shinkeigaku. 2006 Nov;46(11):869.

No abstract available.

Cite
Saida T, Tanaka M, Komori M, et al. [Treatment]. Rinsho Shinkeigaku. 2006;46(11):869
Saida, T., Tanaka, M., Komori, M., & Hao, Q. (2006). [Treatment]. Rinsho shinkeigaku = Clinical neurology, 46(11), 869.
Saida, Takahiko, et al. "[Treatment]." Rinsho shinkeigaku = Clinical neurology vol. 46,11 (2006): 869.
Saida T, Tanaka M, Komori M, Hao Q. [Treatment]. Rinsho Shinkeigaku. 2006 Nov;46(11):869. Japanese. PMID: 17432204.
Copy Download .nbib Format: NLM
Confusing Cochrane reviews on treatment in multiple sclerosis.

The Lancet. Neurology

de Jong BA, Engelen M, van Schaik IN, Vermeulen M.
PMID: 15907736
Lancet Neurol. 2005 Jun;4(6):330-1. doi: 10.1016/S1474-4422(05)70081-8.

No abstract available.

Cite
de Jong BA, Engelen M, van Schaik IN, et al. Confusing Cochrane reviews on treatment in multiple sclerosis. Lancet Neurol. 2005;4(6):330-1doi: 10.1016/S1474-4422(05)70081-8.
de Jong, B. A., Engelen, M., van Schaik, I. N., & Vermeulen, M. (2005). Confusing Cochrane reviews on treatment in multiple sclerosis. The Lancet. Neurology, 4(6), 330-1. https://doi.org/10.1016/S1474-4422(05)70081-8
de Jong, Brigit A, et al. "Confusing Cochrane reviews on treatment in multiple sclerosis." The Lancet. Neurology vol. 4,6 (2005): 330-1. doi: https://doi.org/10.1016/S1474-4422(05)70081-8
de Jong BA, Engelen M, van Schaik IN, Vermeulen M. Confusing Cochrane reviews on treatment in multiple sclerosis. Lancet Neurol. 2005 Jun;4(6):330-1. doi: 10.1016/S1474-4422(05)70081-8. PMID: 15907736.
Copy Download .nbib Format: NLM
[Diagnosis and treatment of multiple sclerosis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Zavalishin IA, Peresedova AV, Stoĭda NI, Gur'ianova OE, Arzumian NSh, Alekseeva NS, Eliseeva DD, Gulevskaia TS, Briukhov VV.
PMID: 21905343
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(6):89-96.

No abstract available.

Cite
Zavalishin IA, Peresedova AV, Stoĭda NI, et al. [Diagnosis and treatment of multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(6):89-96
Zavalishin, I. A., Peresedova, A. V., Stoĭda, N. I., Gur'ianova, O. E., Arzumian, N. S. h., Alekseeva, N. S., Eliseeva, D. D., Gulevskaia, T. S., & Briukhov, V. V. (2011). [Diagnosis and treatment of multiple sclerosis]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 111(6), 89-96.
Zavalishin, I A, et al. "[Diagnosis and treatment of multiple sclerosis]." Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova vol. 111,6 (2011): 89-96.
Zavalishin IA, Peresedova AV, Stoĭda NI, Gur'ianova OE, Arzumian NSh, Alekseeva NS, Eliseeva DD, Gulevskaia TS, Briukhov VV. [Diagnosis and treatment of multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(6):89-96. Russian. PMID: 21905343.
Copy Download .nbib Format: NLM
Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.

Applied health economics and health policy

Hawton A, Shearer J, Goodwin E, Green C.
PMID: 23637055
Appl Health Econ Health Policy. 2013 Aug;11(4):331-41. doi: 10.1007/s40258-013-0034-0.

BACKGROUND: Multiple sclerosis (MS) is a chronic neurological disorder, which can lead to a wide range of disabling symptoms. The condition has a significant negative impact on health-related quality of life, and the economic cost of the disease is...

Cite
Hawton A, Shearer J, Goodwin E, et al. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Appl Health Econ Health Policy. 2013;11(4):331-41doi: 10.1007/s40258-013-0034-0.
Hawton, A., Shearer, J., Goodwin, E., & Green, C. (2013). Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Applied health economics and health policy, 11(4), 331-41. https://doi.org/10.1007/s40258-013-0034-0
Hawton, Annie, et al. "Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis." Applied health economics and health policy vol. 11,4 (2013): 331-41. doi: https://doi.org/10.1007/s40258-013-0034-0
Hawton A, Shearer J, Goodwin E, Green C. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Appl Health Econ Health Policy. 2013 Aug;11(4):331-41. doi: 10.1007/s40258-013-0034-0. PMID: 23637055.
Copy Download .nbib Format: NLM
Recent advances in network medicine: From disease mechanisms to new treatment strategies.

Multiple sclerosis (Houndmills, Basingstoke, England)

Faria do Valle Í.
PMID: 31965895
Mult Scler. 2020 Apr;26(5):609-615. doi: 10.1177/1352458519877002. Epub 2020 Jan 22.

Conventional reductionist approaches have guided most of our understanding in disease diagnostic and treatment. However, most diseases are not consequence of perturbations in a single protein or metabolite, but rather of the effect that these perturbations have in their...

Cite
Faria do Valle Í. Recent advances in network medicine: From disease mechanisms to new treatment strategies. Mult Scler. 2020;26(5):609-615doi: 10.1177/1352458519877002.
Faria do Valle, �. �. (2020). Recent advances in network medicine: From disease mechanisms to new treatment strategies. Multiple sclerosis (Houndmills, Basingstoke, England), 26(5), 609-615. https://doi.org/10.1177/1352458519877002
Faria do Valle, Ítalo. "Recent advances in network medicine: From disease mechanisms to new treatment strategies." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 26,5 (2020): 609-615. doi: https://doi.org/10.1177/1352458519877002
Faria do Valle Í. Recent advances in network medicine: From disease mechanisms to new treatment strategies. Mult Scler. 2020 Apr;26(5):609-615. doi: 10.1177/1352458519877002. Epub 2020 Jan 22. PMID: 31965895.
Copy Download .nbib Format: NLM
Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)

Waubant E.
PMID: 32648815
Mult Scler. 2020 Oct;26(12):1474-1475. doi: 10.1177/1352458520936243. Epub 2020 Jul 10.

No abstract available.

Cite
Waubant E. Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary. Mult Scler. 2020;26(12):1474-1475doi: 10.1177/1352458520936243.
Waubant, E. (2020). Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary. Multiple sclerosis (Houndmills, Basingstoke, England), 26(12), 1474-1475. https://doi.org/10.1177/1352458520936243
Waubant, Emmanuelle. "Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 26,12 (2020): 1474-1475. doi: https://doi.org/10.1177/1352458520936243
Waubant E. Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary. Mult Scler. 2020 Oct;26(12):1474-1475. doi: 10.1177/1352458520936243. Epub 2020 Jul 10. PMID: 32648815.
Copy Download .nbib Format: NLM
Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes.

Current opinion in neurology

Brichetto G, Zaratin P.
PMID: 32324704
Curr Opin Neurol. 2020 Jun;33(3):295-299. doi: 10.1097/WCO.0000000000000821.

PURPOSE OF REVIEW: Patient-reported outcome (PRO) represents a unique opportunity to measure the impact of health research, and care on outcomes that matter most to people with multiple sclerosis (PwMS).RECENT FINDINGS: How to incorporate PROs in MS clinical trials...

Cite
Brichetto G, Zaratin P. Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Curr Opin Neurol. 2020;33(3):295-299doi: 10.1097/WCO.0000000000000821.
Brichetto, G., & Zaratin, P. (2020). Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Current opinion in neurology, 33(3), 295-299. https://doi.org/10.1097/WCO.0000000000000821
Brichetto, Giampaolo, and Zaratin, Paola. "Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes." Current opinion in neurology vol. 33,3 (2020): 295-299. doi: https://doi.org/10.1097/WCO.0000000000000821
Brichetto G, Zaratin P. Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Curr Opin Neurol. 2020 Jun;33(3):295-299. doi: 10.1097/WCO.0000000000000821. PMID: 32324704; PMCID: PMC7259382.
Copy Download .nbib Format: NLM
Can new chemical therapies improve the management of multiple sclerosis in children?.

Expert opinion on pharmacotherapy

D'Amico E, Zanghì A, Patti F.
PMID: 27901353
Expert Opin Pharmacother. 2017 Jan;18(1):45-55. doi: 10.1080/14656566.2016.1267139. Epub 2016 Dec 16.

INTRODUCTION: Pediatric multiple sclerosis (MS) may represent up to 10% of all MS cases. Establishing the diagnosis of MS in a child is complicated by the limited diagnostic criteria and the possibility of significant overlap with acute disseminated encephalomyelitis....

Cite
D'Amico E, Zanghì A, Patti F. Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opin Pharmacother. 2016;18(1):45-55doi: 10.1080/14656566.2016.1267139.
D'Amico, E., Zanghì, A., & Patti, F. (2017). Can new chemical therapies improve the management of multiple sclerosis in children?. Expert opinion on pharmacotherapy, 18(1), 45-55. https://doi.org/10.1080/14656566.2016.1267139
D'Amico, Emanuele, et al. "Can new chemical therapies improve the management of multiple sclerosis in children?." Expert opinion on pharmacotherapy vol. 18,1 (2017): 45-55. doi: https://doi.org/10.1080/14656566.2016.1267139
D'Amico E, Zanghì A, Patti F. Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opin Pharmacother. 2017 Jan;18(1):45-55. doi: 10.1080/14656566.2016.1267139. Epub 2016 Dec 16. PMID: 27901353.
Copy Download .nbib Format: NLM
Treatment decisions in MS: Shifting the goal posts or changing how we see them?.

Multiple sclerosis (Houndmills, Basingstoke, England)

Mahajan KR, Nakamura K, Ontaneda D.
PMID: 30234433
Mult Scler. 2018 Oct;24(12):1523-1525. doi: 10.1177/1352458518801479. Epub 2018 Sep 20.

No abstract available.

Cite
Mahajan KR, Nakamura K, Ontaneda D. Treatment decisions in MS: Shifting the goal posts or changing how we see them?. Mult Scler. 2018;24(12):1523-1525doi: 10.1177/1352458518801479.
Mahajan, K. R., Nakamura, K., & Ontaneda, D. (2018). Treatment decisions in MS: Shifting the goal posts or changing how we see them?. Multiple sclerosis (Houndmills, Basingstoke, England), 24(12), 1523-1525. https://doi.org/10.1177/1352458518801479
Mahajan, Kedar R, et al. "Treatment decisions in MS: Shifting the goal posts or changing how we see them?." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 24,12 (2018): 1523-1525. doi: https://doi.org/10.1177/1352458518801479
Mahajan KR, Nakamura K, Ontaneda D. Treatment decisions in MS: Shifting the goal posts or changing how we see them?. Mult Scler. 2018 Oct;24(12):1523-1525. doi: 10.1177/1352458518801479. Epub 2018 Sep 20. PMID: 30234433.
Copy Download .nbib Format: NLM
Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics.

Medicinal chemistry (Shariqah (United Arab Emirates))

Katsara M, Apostolopoulos V.
PMID: 29453907
Med Chem. 2018 Feb 06;14(2):104-105. doi: 10.2174/157340641402180206092504.

No abstract available.

Cite
Katsara M, Apostolopoulos V. Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics. Med Chem. 2018;14(2):104-105doi: 10.2174/157340641402180206092504.
Katsara, M., & Apostolopoulos, V. (2018). Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics. Medicinal chemistry (Shariqah (United Arab Emirates)), 14(2), 104-105. https://doi.org/10.2174/157340641402180206092504
Katsara, Maria, and Apostolopoulos, Vasso. "Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics." Medicinal chemistry (Shariqah (United Arab Emirates)) vol. 14,2 (2018): 104-105. doi: https://doi.org/10.2174/157340641402180206092504
Katsara M, Apostolopoulos V. Editorial: Multiple Sclerosis: Pathogenesis and Therapeutics. Med Chem. 2018 Feb 06;14(2):104-105. doi: 10.2174/157340641402180206092504. PMID: 29453907.
Copy Download .nbib Format: NLM
Cancer specific risk in multiple sclerosis patients.

Critical reviews in oncology/hematology

Kyritsis AP, Boussios S, Pavlidis N.
PMID: 26481954
Crit Rev Oncol Hematol. 2016 Feb;98:29-34. doi: 10.1016/j.critrevonc.2015.10.002. Epub 2015 Oct 09.

Multiple sclerosis (MS) is a chronic central nervous system (CNS) autoimmune disease. Studies of cancer risk in MS patients have shown inconsistent findings. A pubmed search of the literature on cancer risk in patients with MS was conducted and...

Cite
Kyritsis AP, Boussios S, Pavlidis N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol. 2015;98:29-34doi: 10.1016/j.critrevonc.2015.10.002.
Kyritsis, A. P., Boussios, S., & Pavlidis, N. (2016). Cancer specific risk in multiple sclerosis patients. Critical reviews in oncology/hematology, 9829-34. https://doi.org/10.1016/j.critrevonc.2015.10.002
Kyritsis, Athanasios P, et al. "Cancer specific risk in multiple sclerosis patients." Critical reviews in oncology/hematology vol. 98 (2016): 29-34. doi: https://doi.org/10.1016/j.critrevonc.2015.10.002
Kyritsis AP, Boussios S, Pavlidis N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol. 2016 Feb;98:29-34. doi: 10.1016/j.critrevonc.2015.10.002. Epub 2015 Oct 09. PMID: 26481954.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 46 entries